Shots: •      The NDA filling is based on results of P-III SAMURAI and SPARTAN study assessing Lasmiditan vs PBO in patients with migrane with or without aura in adults •     The collective results of the study demonstrated safety and efficacy of Lasmiditan- meeting all 1EP & 2EP- showing greater percentage of patients free of their most bothersome symptom (MBS) •      Lasmiditan is a selective serotonin 5-HT1F agonist and is developed for acute treatment of migrane in adults Ref: Eli Lilly | Image: Wall Street Journal